Ponatinib in Chronic Myeloid Leukemia Patients in Chronic Phase
Recruiting
Observational Study
Chronic Myeloid Leukemia, Chronic Phase
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- University of Pisa · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this retrospective observational study is to evaluate any possible association between plasma concentrations of ponatinib and its pharmacodynamics (efficacy/tolerability) in patients affected by chronic myeloid leukemia in chronic phase (CML-CP).
In particular, the aims of the study will be:
* primary aim: to investigate the relationships (if any) between plasma concentrations and ac…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Patients will be enrolled according the following inclusion criteria:
* Subjects ≥18 years old affected by CML
* Patients being treated with ponatinib at a dose of 45, 30 or 15 mg/day for more than 14 days
* Patients who have provided informed consent to the study
Exclusion criteria:
* Subjects \…
Contacts